CraniUS, an R&D company focused on building groundbreaking treatments for patients with chronic brain disease, today announced the closing of a $19.4 million Series A fundraising round. The Series A round, funded entirely by private investors, will drive the development of CraniUS' flagship device as it moves towards FDA approval for a first-in-human clinical study.

CraniUS' stated mission is to invent and engineer world-class technology to define the future of diagnostics and treatments for patients with chronic brain disease. Its flagship device is being specifically developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective. CraniUS utilizes novel pump and wireless charging technology to enable long-term and direct medicine administration via CED (convection-enhanced delivery), a promising method of medicine delivery first introduced by the National Institute of Health (NIH).